CLINICAL TRIALS PROFILE FOR VARENICLINE TARTRATE
✉ Email this page to a colleague
All Clinical Trials for varenicline tartrate
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00141167 ↗ | A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation | Completed | Pfizer | Phase 3 | 2005-02-01 | The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo for smoking cessation. |
NCT00141206 ↗ | A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation | Completed | Pfizer | Phase 3 | 2003-05-01 | The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation. |
NCT00143299 ↗ | A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline | Completed | Pfizer | Phase 3 | 2003-10-01 | The primary purpose of this study is to obtain safety information on cigarette smokers treated with 52 weeks of varenicline regardless of smoking status. |
NCT00143325 ↗ | An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation | Completed | Pfizer | Phase 3 | 2005-01-01 | Open-label comparison of standard 12-week regimen of varenicline with standard 10-week regimen of transdermal nicotine patch for smoking cessation. |
NCT00143364 ↗ | A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation | Completed | Pfizer | Phase 3 | 2003-06-01 | The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation. |
NCT00282984 ↗ | Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking | Completed | Pfizer | Phase 3 | 2006-02-01 | The primary purpose of this study is to determine whether or not varenicline will help people with cardiovascular disease quit smoking and to confirm it is safe in these patients. |
NCT00285012 ↗ | Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD). | Completed | Pfizer | Phase 3 | 2006-05-01 | This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for varenicline tartrate
Condition Name
Clinical Trial Locations for varenicline tartrate
Trials by Country
Clinical Trial Progress for varenicline tartrate
Clinical Trial Phase
Clinical Trial Sponsors for varenicline tartrate
Sponsor Name